capecitabine fresenius kabi 500 mg tabletki powlekane
fresenius kabi polska sp. z o.o. - capecitabinum - tabletki powlekane - 500 mg
tenofovir disoproxil accordpharma 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - tenofovirum disoproxilum - tabletki powlekane - 245 mg
travoprost + timolol medical valley (40 mcg + 5 mg)/ml krople do oczu, roztwór
medical valley invest ab - travoprostum + timololum - krople do oczu, roztwór - (40 mcg + 5 mg)/ml
cabazitaxel medical valley 60 mg koncentrat i rozpuszczalnik do sporządzania roztworu do infuzji
medical valley invest ab - cabazitaxelum - koncentrat i rozpuszczalnik do sporządzania roztworu do infuzji - 60 mg
dabigatran etexilate +pharma 110 mg kapsułki twarde
+pharma arzneimittel gmbh - dabigatranu eteksylan w postaci mezylanu - kapsułki twarde - 110 mg
cisatracurium accordpharma 2 mg/ml roztwór do wstrzykiwań / do infuzji
accord healthcare polska sp. z o.o. - cisatracurii besilas - roztwór do wstrzykiwań / do infuzji - 2 mg/ml
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
volulyte 6% - roztwór do infuzji
fresenius kabi deutschland gmbh - poli (o-2-hydroksyetylo) skrobia + sodu octan trójwodny + sodu chlorek + potasu chlorek + magnezu chlorek sześciowodny - roztwór do infuzji - -
depepsit met 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg
depepsit met 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg